LEP and myelodysplastic syndrome: MDS patients with a progressive disease during follow-up had a hypermethylated LEP promoter already at the time of diagnosis compared to those with a stable disease (p = 0.045), whereas this was not significantly different in CCUS patients (Additional file 2: Fig. S3).